Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.979 SEK | +1.87% | +9.26% | +42.09% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+42.09% | 68.38M | C+ | ||
+49.45% | 56.69B | B- | ||
-2.98% | 41B | B | ||
+38.14% | 38.11B | A | ||
-11.22% | 26.89B | C | ||
+15.72% | 25.59B | B- | ||
-22.71% | 18.59B | B | ||
-0.21% | 12.39B | B+ | ||
+27.23% | 11.99B | C+ | ||
+22.73% | 11.88B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ATORX Stock
- Ratings Alligator Bioscience AB